ArticleThe Journal of clinical investigation1996
Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice.
Article in The Journal of clinical investigation, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 152 citations in OpenAlex.
- Oral immune regulation using colitis extracted proteins for treatment of Crohn's disease: results of a phase I clinical trial.World journal of gastroenterology · 2005Trial
- Type 1 diabetes mellitus and its oral tolerance therapy.World journal of diabetes · 2020Review
- Metabolic syndrome - Removing roadblocks to therapy: Antigenic immunotherapies.Molecular metabolism · 2014Review
- Non-antigenic and antigenic interventions in type 1 diabetes.Human vaccines & immunotherapeutics · 2014Review
- Emerging Trends in Noninvasive Insulin Delivery.Journal of pharmaceutics · 2014Review
- Trials in type 1 diabetes: Antigen-specific therapies.Clinical immunology (Orlando, Fla.) · 2013Review
- Inducing immune tolerance: a focus on Type 1 diabetes mellitus.Diabetes management (London, England) · 2013Article
- Article
- The effect of oral tolerance on the roles of small intestinal intraepithelial lymphocytes in murine colitis induced by dextran sodium sulfate.International journal of colorectal disease · 2012Article
- Clinical potential of antigen-specific therapies in type 1 diabetes.The review of diabetic studies : RDS · 2012Review
- 2011 Update: antigen-specific therapy in type 1 diabetes.Current opinion in endocrinology, diabetes, and obesity · 2011Review
- The protective effect of oral colitis-derived proteins in a murine model of inflammatory bowel disease is associated with an increase in gammadelta T cells in large intestinal mucosa.International journal of colorectal disease · 2010Article
- Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Induction of mucosal tolerance in SLE: a sniff or a sip away from ameliorating lupus?Clinical immunology (Orlando, Fla.) · 2009Review
- Review
- AAV8-mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2008Article
- Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization.Current diabetes reports · 2008Review
- Mucosal exposure to antigen: cause or cure of type 1 diabetes?Current diabetes reports · 2007Review
- Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs.The Journal of clinical investigation · 2006Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Oral administration of self-antigens has been proposed as a therapy to prevent and treat autoimmune diseases. Here we report that oral treatment with insulin prevents virus-induced insulin-dependent diabetes mellitus (IDDM) in a transgenic (tg) mouse model. Such mice express the viral nucleoprotein (NP) of lymphocytic choriomeningitis virus (LCMV) under control of the rat insulin promoter in their pancreatic beta cells and < 2% spontaneously develop diabetes. However, 2 mo after challenge with LCMV, IDDM occurs in > 95% of tg mice but not in controls. Oral treatment with 1 mg of insulin twice per week for 2 mo starting either 1 wk before or 10 d after initiating LCMV infection prevents IDDM in > 50% of the tg mice (observation time 8 mo). Thus, insulin therapy is effective in preventing progression to overt IDDM in prediabetic tg mice with ongoing islet infiltration. Oral administration of insulin does not affect the generation of LCMV-NP-specific anti-self cytotoxic T lymphocytes nor the infiltration of lymphocytes into the pancreas. However, less beta cells are destroyed in insulin-treated mice, upregulation of MHC class I and II molecules does not occur, and antiviral (self) cytotoxic T lymphocytes are not found in the islets, events present in tg mice developing IDDM. The majority of lymphocytes in the islets of insulin-treated tg mice without IDDM produces IL-4, IL-10, and TGF-beta. In contrast, lymphocytes from islets of tg mice developing IDDM mainly make gamma-IFN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.